--- title: A New mRNA Flu Vaccine Produces a Broader Antibody Response Than the Standard Shot description: A human trial shows the new mRNA flu vaccine produces a broader, longer-lasting antibody response than the standard shot, though real-world protection is still unproven. author: Darie Nani (Editor-in-Chief) updated: 2026-09-12T13:14:13.859Z canonical: https://richhealthmagazine.com/article/mrna-flu-vaccine-broader-antibody-response-trial categories: Longevity & Science content_type: News region: United States publication: Rich Health Magazine schema_type: Article --- A new human trial has helped explain why the mRNA flu vaccine that just reached the US market may protect differently from the shot you have gotten for years: it produces a broader and longer-lasting antibody response. Researchers led by Associate Professor Jiwon Lee of Korea University College of Medicine, working with Professor Ali Ellebedy's group at Washington University in St. Louis, tracked 75 healthy adults across two flu seasons and found that the people who got the mRNA shot developed a more diverse set of antibodies than those who got a standard vaccine. The [study](https://pmc.ncbi.nlm.nih.gov/articles/PMC13414572/), published in Nature Immunology in June 2026, arrives just as the first mRNA flu vaccine has been cleared for older Americans, and it puts some biology behind the question a lot of people are asking: is this shot actually better? ## The mRNA Group Came Out Ahead on Breadth The trial enrolled 38 adults who received the investigational mRNA vaccine mRNA-1010, Moderna's flu shot, and 37 who received Fluarix, a licensed shot made the traditional way from split flu virus. The participants were aged 20 to 50, with a median age of 30, and the team followed their blood for 26 weeks across the 2022 to 2024 Northern Hemisphere seasons. In a subset, the researchers used ultrasound-guided needle sampling of lymph nodes to watch the germinal centers, the small immune training hubs where B cells refine their antibodies over weeks. Using a mass-spectrometry technique called Ig-Seq to identify individual antibody clones, the researchers measured that breadth clone by clone and found greater increases in neutralizing antibodies against 11 of the 13 A/H1N1 viruses tested. Germinal-center activity specific to flu was still detectable at 26 weeks, roughly six months out, in 5 of 13 mRNA recipients and in none of the Fluarix recipients. ## Flu Drifts Every Season, So a Broader Response Helps Flu drifts from season to season, so a shot that trains antibodies against a wider range of related strains has more chances of still recognizing whatever is circulating months after the needle goes in. A longer-running germinal center helps for the same reason: the longer that training hub stays active, the more time the immune system has to sharpen antibodies that hold up as the season wears on. A broader antibody response is already understood to be a general feature of mRNA vaccines. What is new in this trial is the evidence that the germinal-center activity can last as long as six months, and that the team could measure the response down to individual antibody clones rather than as a single averaged number. ## A Stronger Lab Response Does Not Yet Mean Fewer Infections The trial measured immune-response markers, not whether people actually caught flu less. Antibody breadth, diversity, and germinal-center persistence are signals that the immune system is doing more work, but they are not the same as counting infections. The researchers note that the stronger antibody titers "did not result in significant differences in HAI," a standard laboratory correlate of protection, between the 2022 to 2023 cohorts. They say further studies are needed to determine whether these responses translate into protection across multiple seasons or longer gaps between shots, and whether the benefit holds in older adults and people with weakened immune systems, groups this young, healthy trial did not test. In its Phase 3 trial, Moderna's mRNA-1010 showed about 26.6% relative efficacy against flu compared with a standard shot in older adults, a [modest, incremental gain](https://www.cidrap.umn.edu/influenza-vaccines/phase-3-trial-finds-moderna-mrna-flu-vaccine-outperforms-standard-vaccine-older). It also came with more short-term discomfort: injection-site pain was reported by about 66% of mRNA recipients versus about 30% of those who got the standard shot. ## An mRNA Flu Shot Is Now Approved, and Federal Funding Was Just Cut The mRNA flu shot is no longer hypothetical. The FDA approved Moderna's mRNA-1010, sold as mFLUSIVA, on August 5, 2026, an accelerated approval for adults 65 and older that is conditional on a two-year post-marketing study confirming its efficacy. Pfizer and BioNTech have their own mRNA flu candidate in late-stage testing, strong against influenza A but weaker on B strains, while Sanofi has stepped back from mRNA flu. In 2025 the federal government cut roughly $500 million in mRNA vaccine development contracts through its biomedical research agencies, and senior US health officials have publicly questioned mRNA vaccines for respiratory infections. For a reader weighing the mRNA shot this season, the broader antibody response is real and measurable. Whether it adds up to meaningfully fewer infections, especially in the older adults it was approved for, is what the ongoing studies still have to show. ## FAQ **Q: Did the FDA approve an mRNA flu vaccine?** Yes. The FDA approved Moderna's mRNA flu vaccine, mRNA-1010 (sold as mFLUSIVA), on August 5, 2026. It is an accelerated approval for adults 65 and older, conditional on a two-year post-marketing study confirming its efficacy. **Q: Is an mRNA flu vaccine available in 2026?** An mRNA flu vaccine received US approval in August 2026 for adults 65 and older. Other candidates, including one from Pfizer and BioNTech, are still in late-stage testing. **Q: Is the mRNA flu vaccine better than the regular flu shot?** It depends on what better means. The new trial shows the mRNA shot produces a broader and longer-lasting antibody response than a standard shot, and Moderna's Phase 3 trial found about 26.6% higher relative efficacy in older adults, a modest gain. But the antibody findings measure an immune-response marker, not confirmed real-world protection, and the mRNA shot caused more injection-site pain. **Q: What vaccines currently use mRNA?** mRNA technology is used in the COVID-19 vaccines from Moderna and Pfizer-BioNTech, and now in Moderna's newly approved flu vaccine. Additional mRNA flu and respiratory vaccines are in development.